This proposal is for the purchase of a SkyScan 1176 In-vivo Micro CT system, which will add new capabilities to our core of users. The seventeen laboratories collaborating in this venture are involved in a wide range of NIH-funded ventures, and we have a history of working together successfully in this shared facility. To facilitate administration of this shared equipment we have partnered with the Indiana Institute for Biomedical Imaging Sciences, who provide campus-wide assistance with biomedical imaging. The request for a Skyscan 1176 system has a three-fold rationale: adding in vivo scanning capability, allowing large specimen ex vivo scanning, and reducing capacity on the present CT system. The present micro CT system (a SkyScan 1172, obtained in 2007) provides excellent imaging of mineralized tissues, but can be used only for ex vivo specimens. The SkyScan 1176 will enable researchers to utilize experimental protocols that can monitor the changes in tissue over time in their experimental animals, thereby provided longitudinal data while simultaneously using fewer animals. The SkyScan 1176 will also allow the scanning of larger intact specimens (like pig hearts and human kidneys) which cannot be accommodated on the present system. With regard to capacity, the present system cannot handle the high volume of micro CT imaging demanded by NIH-funded projects on this campus. The SkyScan 1176 can be used to scan many of the specimens now being scanned on the old 1172 system, with identical parameters, and so relieve pressure on the present facility. The SkyScan 1176 system is complementary to the presently existing system. This means that minimal retraining will be required for present users. Moreover, for most users the two systems can be used interchangeably, so that the present full load on the existing system can be relieved, thus allowing every laboratory to obtain data on its specimens in a timely manner.
This proposal is for purchase of a new micro CT (cat scanner) system, which will be used to study biological specimens from several laboratories. This technology will make possible new discoveries in the areas of bone disease (such as osteoporosis), blood vessel disease (including the changes in blood vessel growth in diabetes), tooth decay, and kidney stone disease.
|Allen, Matthew R; McNerny, Erin; Aref, Mohammad et al. (2017) Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model. PLoS One 12:e0181750|
|Meixner, Cory N; Aref, Mohammad W; Gupta, Aryaman et al. (2017) Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. Calcif Tissue Int 101:75-81|
|Larsen, Rachel A; Peveler, Jessica L; Klutzke, Joshuah B et al. (2017) Effects of daily restraint with and without injections on skeletal properties in C57BL/6NHsd mice. Lab Anim (NY) 46:299-301|
|Aref, M W; McNerny, E M B; Brown, D et al. (2016) Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes. Osteoporos Int 27:3637-3643|
|Ibrahim, El-Sayed H; Cernigliaro, Joseph G; Pooley, Robert A et al. (2016) Detection of different kidney stone types: an ex vivo comparison of ultrashort echo time MRI to reference standard CT. Clin Imaging 40:90-5|